Evaxion Biotech A/S ADR (EVAX)

$1.66 +0.02 (1.22%)
Market Cap 2.30M
Revenue (ttm) 3.34M
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -316.47%
Debt to Equity Ratio -4.95
Volume 57,600
Avg Vol 68,002
Day's Range N/A - N/A
Shares Out 1.40M
Stochastic %K 76%
Beta -0.24
Analysts Strong Sell
Price Target $13.25

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a m...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 53 53 18 50
Website: evaxion.ai
Address:
Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark
Whtmtn
Whtmtn Aug. 3 at 8:25 PM
$EVAX I do not have a good feeling about this one. Helen has learned from the best on how to fleece investors. Out of cash by Q1 '27 so dilution is coming if they can even raise capital.
1 · Reply
Manwiththeplan
Manwiththeplan Aug. 3 at 3:47 PM
$EVAX Sommerserie: Evaxion-topchef om at være ny i jobbet: Den rette balance tager tid https://share.google/o7IlrVUxQkcOWwvkS
2 · Reply
Teillbou
Teillbou Aug. 3 at 2:34 PM
$EVAX will go bankrupt
0 · Reply
Whtmtn
Whtmtn Aug. 3 at 1:38 PM
$EVAX Helen’s doing a bang up job here. Wonder how much she is paid and how many free options or shares she received.
1 · Reply
Manwiththeplan
Manwiththeplan Aug. 3 at 12:12 PM
$EVAX biggest achievement of last month: they changed the name of the corporate presentation from july to august.
0 · Reply
NoNoNoNoNoNoYesNo
NoNoNoNoNoNoYesNo Jul. 29 at 3:56 PM
$EVAX whats up with that huge bid at 2.80? Over 58k shares...
1 · Reply
Tradezeez
Tradezeez Jul. 25 at 2:59 PM
$EVAX This will take all your moneys comrade!
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 24 at 7:51 PM
$EVAX no volume. I hope ppl.will get interested again towards october. 3 months
0 · Reply
Whtmtn
Whtmtn Jul. 21 at 1:48 PM
$EVAX hey Helen where are those “strategic partnerships” you are perpetually oh so close to securing. Learned well from the ADAP hype. As they say in Texas all hat no cattle until they shut u down.
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 17 at 1:56 PM
$EVAX titel of abstract gives us a lot of information. 'Durable disease control'
0 · Reply
Latest News on EVAX
Evaxion Biotech to present EVX-01 clinical efficacy data at ESMO

2026-07-17T11:40:27.000Z - 18 days ago

Evaxion Biotech to present EVX-01 clinical efficacy data at ESMO

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Jul 17, 2026, 7:15 AM EDT - 18 days ago

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion Biotech presents new data on EVX-V1

2026-07-12T13:45:04.000Z - 23 days ago

Evaxion Biotech presents new data on EVX-V1

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Jul 12, 2026, 9:30 AM EDT - 23 days ago

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop

Jul 1, 2026, 8:00 AM EDT - 4 weeks ago

Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop

Evaxion receives Prix Galien UK Award for Best digital health solution

Jun 12, 2026, 3:00 AM EDT - 7 weeks ago

Evaxion receives Prix Galien UK Award for Best digital health solution

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Jun 11, 2026, 2:00 AM EDT - 7 weeks ago

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

May 12, 2026, 9:30 AM EDT - 3 months ago

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

Evaxion Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Evaxion Earnings Call Transcript: Q1 2026

Evaxion Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Evaxion Earnings release: Q1 2026

Evaxion Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Evaxion Slides: Q1 2026

Evaxion announces business update and first quarter 2026 financial results

May 7, 2026, 7:30 AM EDT - 3 months ago

Evaxion announces business update and first quarter 2026 financial results

Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

May 4, 2026, 8:00 AM EDT - 3 months ago

Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

Evaxion Biotech management to meet with Maxim

2026-04-27T16:25:27.000Z - 3 months ago

Evaxion Biotech management to meet with Maxim

Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer

Evaxion says EVX-01 demonstrates 86% vaccine target precision in trial

2026-04-17T19:15:15.000Z - 3 months ago

Evaxion says EVX-01 demonstrates 86% vaccine target precision in trial

Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Apr 17, 2026, 3:10 PM EDT - 3 months ago

Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Evaxion Biotech announces new data to be presented at AACR meeting

2026-04-17T19:05:59.000Z - 3 months ago

Evaxion Biotech announces new data to be presented at AACR meeting

Evaxion concludes Annual General Meeting

Apr 16, 2026, 11:30 AM EDT - 3 months ago

Evaxion concludes Annual General Meeting

Evaxion Biotech reports last patient visit in one-year extension of EVX-01 trial

2026-04-07T12:55:09.000Z - 4 months ago

Evaxion Biotech reports last patient visit in one-year extension of EVX-01 trial

MRK

Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress

Notice to convene Evaxion's Annual General Meeting

Mar 19, 2026, 9:00 AM EDT - 4 months ago

Notice to convene Evaxion's Annual General Meeting

Evaxion Biotech assumed with a Buy at JonesResearch

2026-03-09T20:11:13.000Z - 5 months ago

Evaxion Biotech assumed with a Buy at JonesResearch

Evaxion Biotech price target lowered to $9 from $11 at Lake Street

2026-03-09T12:45:55.000Z - 5 months ago

Evaxion Biotech price target lowered to $9 from $11 at Lake Street

Evaxion Earnings Call Transcript: Q4 2025

Mar 6, 2026, 8:30 AM EST - 5 months ago

Evaxion Earnings Call Transcript: Q4 2025

Evaxion Annual report: Q4 2025

Mar 6, 2026, 8:30 AM EST - 5 months ago

Evaxion Annual report: Q4 2025

Evaxion Earnings release: Q4 2025

Mar 6, 2026, 8:30 AM EST - 5 months ago

Evaxion Earnings release: Q4 2025

Evaxion Annual report: Q4 2025

Mar 6, 2026, 8:30 AM EST - 5 months ago

Evaxion Annual report: Q4 2025

Evaxion Slides: Q4 2025

Mar 6, 2026, 8:30 AM EST - 5 months ago

Evaxion Slides: Q4 2025

Evaxion Biotech reports Q4 EPS (2c) vs. (21c) last year

2026-03-05T14:36:58.000Z - 5 months ago

Evaxion Biotech reports Q4 EPS (2c) vs. (21c) last year

Evaxion Biotech sees FY26 capex ‘similar’ to FY25

2026-03-05T14:36:19.000Z - 5 months ago

Evaxion Biotech sees FY26 capex ‘similar’ to FY25

Evaxion announces business update and full year 2025 financial results

Mar 5, 2026, 9:28 AM EST - 5 months ago

Evaxion announces business update and full year 2025 financial results

Evaxion Biotech to ‘slightly delay’ filing of 2025 report

2026-03-05T13:42:35.000Z - 5 months ago

Evaxion Biotech to ‘slightly delay’ filing of 2025 report

Evaxion plans to file 2025 annual report later today

Mar 5, 2026, 8:02 AM EST - 5 months ago

Evaxion plans to file 2025 annual report later today

Evaxion to announce business update and full year 2025 financial results on March 5, 2026

Mar 2, 2026, 8:00 AM EST - 5 months ago

Evaxion to announce business update and full year 2025 financial results on March 5, 2026

Evaxion Biotech initiated with a Buy at Maxim

2026-02-19T13:29:15.000Z - 5 months ago

Evaxion Biotech initiated with a Buy at Maxim

Evaxion Biotech expands AI-Immunology platform into autoimmune diseases

2026-01-13T13:26:14.000Z - 7 months ago

Evaxion Biotech expands AI-Immunology platform into autoimmune diseases

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Jan 13, 2026, 8:00 AM EST - 7 months ago

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Jan 7, 2026, 8:00 AM EST - 7 months ago

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Dec 19, 2025, 7:00 AM EST - 8 months ago

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Evaxion Transcript: Sidoti's Year End Virtual Investor Conference

Dec 11, 2025, 8:30 AM EST - 8 months ago

Evaxion Transcript: Sidoti's Year End Virtual Investor Conference

Evaxion Biotech presents new data for EVX-04

2025-12-07T18:15:11.000Z - 8 months ago

Evaxion Biotech presents new data for EVX-04

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Dec 6, 2025, 2:00 PM EST - 8 months ago

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Evaxion Biotech files to sell 38.45M ordinary shares for holders

2025-11-21T13:50:16.000Z - 9 months ago

Evaxion Biotech files to sell 38.45M ordinary shares for holders

Evaxion Registration statement: Registration Filing

Nov 21, 2025, 7:00 AM EST - 9 months ago

Evaxion Registration statement: Registration Filing

Evaxion Biotech announces data for CMV vaccine program EVX-V1

2025-11-20T13:10:30.000Z - 9 months ago

Evaxion Biotech announces data for CMV vaccine program EVX-V1

Evaxion announce 2026 financial calendar

Nov 12, 2025, 8:00 AM EST - 9 months ago

Evaxion announce 2026 financial calendar

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Nov 7, 2025, 5:10 PM EST - 9 months ago

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Evaxion Earnings Call Transcript: Q3 2025

Evaxion Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Evaxion Earnings release: Q3 2025

Evaxion Biotech reports Q3 EPS 1c vs (4c) last year

2025-11-06T12:46:47.000Z - 9 months ago

Evaxion Biotech reports Q3 EPS 1c vs (4c) last year

Evaxion announces business update and third quarter 2025 financial results

Nov 6, 2025, 7:30 AM EST - 9 months ago

Evaxion announces business update and third quarter 2025 financial results

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Nov 3, 2025, 9:00 AM EST - 9 months ago

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 9:05 AM EDT - 9 months ago

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 8:00 AM EDT - 9 months ago

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Evaxion Transcript: Study Update

Oct 22, 2025, 10:30 AM EDT - 10 months ago

Evaxion Transcript: Study Update

Evaxion Press release: Study Update

Oct 22, 2025, 10:30 AM EDT - 10 months ago

Evaxion Press release: Study Update

Evaxion Slides: Study Update

Oct 22, 2025, 10:30 AM EDT - 10 months ago

Evaxion Slides: Study Update

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Oct 17, 2025, 8:15 AM EDT - 10 months ago

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion Slides: Corporate Presentation

Oct 15, 2025, 7:00 AM EDT - 10 months ago

Evaxion Slides: Corporate Presentation

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Oct 13, 2025, 8:00 AM EDT - 10 months ago

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Oct 8, 2025, 8:12 AM EDT - 10 months ago

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 10 months ago

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Evaxion Transcript: Investor Update

Sep 25, 2025, 8:30 AM EDT - 11 months ago

Evaxion Transcript: Investor Update

Evaxion Press release: Investor Update

Sep 25, 2025, 8:30 AM EDT - 11 months ago

Evaxion Press release: Investor Update

Evaxion Slides: Investor Update

Sep 25, 2025, 8:30 AM EDT - 11 months ago

Evaxion Slides: Investor Update

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Sep 25, 2025, 7:00 AM EDT - 11 months ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Evaxion Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Evaxion Earnings Call Transcript: Q2 2025

Evaxion Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Evaxion Earnings release: Q2 2025

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 25, 2025, 9:00 AM EDT - 1 year ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Evaxion finalizes agreement with EIB to convert debt into equity

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jul 1, 2025, 8:30 AM EDT - 1 year ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 25, 2025, 8:00 AM EDT - 1 year ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion receives grant funding to design new polio vaccine

Jun 3, 2025, 9:15 AM EDT - 1 year ago

Evaxion receives grant funding to design new polio vaccine

Evaxion Earnings Call Transcript: Q1 2025

May 27, 2025, 8:30 AM EDT - 1 year ago

Evaxion Earnings Call Transcript: Q1 2025

Evaxion Earnings release: Q1 2025

May 27, 2025, 8:30 AM EDT - 1 year ago

Evaxion Earnings release: Q1 2025

Evaxion announces business update and first quarter 2025 financial results

May 27, 2025, 7:30 AM EDT - 1 year ago

Evaxion announces business update and first quarter 2025 financial results

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 23, 2025, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

Evaxion Transcript: Sidoti May Micro-Cap Virtual Conference

May 22, 2025, 12:15 PM EDT - 1 year ago

Evaxion Transcript: Sidoti May Micro-Cap Virtual Conference

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

May 22, 2025, 8:00 AM EDT - 1 year ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 28, 2025, 8:00 AM EDT - 1 year ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Evaxion to present at World Vaccine Congress

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Evaxion to present at World Vaccine Congress

Evaxion Transcript: Jones Healthcare and Technology Innovation Conference 2025

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Evaxion Transcript: Jones Healthcare and Technology Innovation Conference 2025

Evaxion Earnings Call Transcript: Q4 2024

Apr 1, 2025, 8:30 AM EDT - 1 year ago

Evaxion Earnings Call Transcript: Q4 2024

Evaxion Annual report: Q4 2024

Apr 1, 2025, 8:30 AM EDT - 1 year ago

Evaxion Annual report: Q4 2024

Evaxion Earnings release: Q4 2024

Apr 1, 2025, 8:30 AM EDT - 1 year ago

Evaxion Earnings release: Q4 2024

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion Registration statement: Registration Filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Evaxion Registration statement: Registration Filing

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Feb 25, 2025, 8:00 AM EST - 1 year ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Evaxion Transcript: Fireside Chat

Feb 19, 2025, 10:00 AM EST - 1 year ago

Evaxion Transcript: Fireside Chat

Evaxion announces closing of $10.8 million public offering

Jan 31, 2025, 4:05 PM EST - 1 year ago

Evaxion announces closing of $10.8 million public offering

Evaxion announces pricing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 1 year ago

Evaxion announces pricing of $10.8 million public offering

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 28, 2025, 8:15 AM EST - 1 year ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Whtmtn
Whtmtn Aug. 3 at 8:25 PM
$EVAX I do not have a good feeling about this one. Helen has learned from the best on how to fleece investors. Out of cash by Q1 '27 so dilution is coming if they can even raise capital.
1 · Reply
Manwiththeplan
Manwiththeplan Aug. 3 at 3:47 PM
$EVAX Sommerserie: Evaxion-topchef om at være ny i jobbet: Den rette balance tager tid https://share.google/o7IlrVUxQkcOWwvkS
2 · Reply
Teillbou
Teillbou Aug. 3 at 2:34 PM
$EVAX will go bankrupt
0 · Reply
Whtmtn
Whtmtn Aug. 3 at 1:38 PM
$EVAX Helen’s doing a bang up job here. Wonder how much she is paid and how many free options or shares she received.
1 · Reply
Manwiththeplan
Manwiththeplan Aug. 3 at 12:12 PM
$EVAX biggest achievement of last month: they changed the name of the corporate presentation from july to august.
0 · Reply
NoNoNoNoNoNoYesNo
NoNoNoNoNoNoYesNo Jul. 29 at 3:56 PM
$EVAX whats up with that huge bid at 2.80? Over 58k shares...
1 · Reply
Tradezeez
Tradezeez Jul. 25 at 2:59 PM
$EVAX This will take all your moneys comrade!
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 24 at 7:51 PM
$EVAX no volume. I hope ppl.will get interested again towards october. 3 months
0 · Reply
Whtmtn
Whtmtn Jul. 21 at 1:48 PM
$EVAX hey Helen where are those “strategic partnerships” you are perpetually oh so close to securing. Learned well from the ADAP hype. As they say in Texas all hat no cattle until they shut u down.
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 17 at 1:56 PM
$EVAX titel of abstract gives us a lot of information. 'Durable disease control'
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 17 at 12:18 PM
$EVAX a personalized cancer vaccine, induces sustained T-cell responses and durable disease control in advanced melanoma after three-year of follow-up
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 17 at 11:54 AM
$EVAX Evaxion to present three-year clinical efficacy data for https://share.google/tYjsIcpAKkBgh3O3k
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 15 at 6:31 PM
$EVAX which will make me rich first? $EVAX or $BCTX ?
1 · Reply
Manwiththeplan
Manwiththeplan Jul. 14 at 4:14 PM
$EVAX
1 · Reply
AlertsAndNews
AlertsAndNews Jul. 12 at 10:18 PM
$EVAX Headline here this morning. Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1 "The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1 EVX-V1 is a next-generation, multi-component vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens"
0 · Reply
Lenni_D
Lenni_D Jul. 12 at 7:05 PM
$EVAX https://evaxion.ai/investors/press-releases/?press_release_id=11241
1 · Reply
focafoca99
focafoca99 Jul. 12 at 1:42 PM
$EVAX presented new preclinical data on its AI-driven CMV vaccine EVX-V1 at the International Herpesvirus Workshop in Montreal.
0 · Reply
Lenni_D
Lenni_D Jul. 1 at 12:13 PM
$EVAX https://evaxion.ai/investors/press-releases/?press_release_id=11226 Blah blah. Wake us up when you have a deal. Nothing but great science and no deals here. This can explode on a couple of deals or it can die a slow death. Amazing pipeline but no Pharma or large biotech is biting so far.
2 · Reply
STACKD0E
STACKD0E Jul. 1 at 12:10 PM
$LGO $BTQ $ALM $HIND $EVAX ✨️
0 · Reply
It_S_Me
It_S_Me Jun. 29 at 7:20 PM
$EVAX evax is huge opportunity
0 · Reply
topstockalerts
topstockalerts Jun. 26 at 11:46 PM
After Hours Top Gainers PT2 $QH $EVAX $BATL $REFR $YDKG
0 · Reply
Tradezeez
Tradezeez Jun. 19 at 2:33 PM
$EVAX Back into the abyss we go…
0 · Reply